A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Part of paid clinical trials in Lake Forest, California.
- Sponsor
- Genentech, Inc.
- Study ID
- NCT07144111
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Hepatic Impairment
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Accepted
Interventions
- Inavolisib — DRUGParticipants will receive a single oral dose of inavolisib
Study Details
This open-label study will evaluate the effect on the pharmacokinetics (PK), safety, and tolerability of a single oral dose of inavolisib in participants with moderate or severe hepatic impairment compared with demographically matched healthy participants with normal hepatic function.
Key Dates
- Start date
- Aug 21, 2025
- Status verified
- Jun 2026
- Primary completion
- Sep 4, 2026
- Completion
- Sep 6, 2026
Study Design
- Enrollment
- 32 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1Participants with normal hepatic function will receive a single oral dose of inavolisib on Day 1
- Experimental: Cohort 2Participants with moderate hepatic function will receive a single oral dose of inavolisib on Day 1
- Experimental: Cohort 3Participants with severe hepatic function will receive a single oral dose of inavolisib on Day 1
Primary Outcome Measure
Maximum Observed Concentration (Cmax) of Inavolisib [ Time Frame: Pre-dose (0 hour), 30 minutes (min), 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose ]
Central Contacts
- Reference Study ID Number: GP45942 https://forpatients.roche.com888-662-6728 (U.S. and Canada)
- Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Orange County Research Center | Lake Forest | California | 92630 | - |
| Orlando Clinical Research Center | Orlando | Florida | 32809 | - |
| Pinnacle Clinical Research - San Antonio | San Antonio | Texas | 78229 | - |
| The Texas Liver Institute, Inc. | San Antonio | Texas | 78215 | - |
Find similar trials in Lake Forest, CA
Related Studies
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434PHASE1 · Recruiting · Vir Biotechnology, Inc. · Rialto, California
- Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentPHASE1 · Recruiting · Daiichi Sankyo · Miami, Florida
- Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionPHASE1 · Recruiting · Atea Pharmaceuticals, Inc. · Orlando, Florida
- Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)PHASE1 · Recruiting · Exelixis · Orlando, Florida